Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company founded in 2018, focused on rare and orphan skin diseases. Lead program QRX003 received FDA Rare Pediatric Disease Designation for Netherton Syndrome. Pipeline includes Peeling Skin Syndrome, Epidermolysis Bullosa, and other rare dermatoses.